You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-Grade Ovarian

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

High-Grade Ovarian Cancer Terms of Homologous Recombination

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • Standard of care
  • (no location specified)
Oct 7, 2022

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer Trial in Toronto (Niraparib)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Sunnybrook Research Institute
Jul 18, 2023

Ovarian Carcinoma Trial (Presence of sarcopenia evaluated prior to neoadjuvant chemo and during chemo as part of optimised

Not yet recruiting
  • Ovarian Carcinoma
  • Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).
  • (no location specified)
Jun 10, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (3 cycles chemo instead of 6 cycles chemo, 6 cycles

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • 3 cycles chemotherapy instead of 6 cycles chemotherapy
  • 6 cycles chemotherapy
  • (no location specified)
Jul 12, 2022

Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer Trial in Worldwide (Speiser-catheter for uterine and tubal lavage)

Completed
  • Ovarian Epithelial Cancer
  • +2 more
  • Speiser-catheter for uterine and tubal lavage
  • Graz, Austria
  • +8 more
Sep 1, 2022

High Grade Serous Ovarian Cancer (HGSOC) Trial (FAPI PET CT)

Not yet recruiting
  • High Grade Serous Ovarian Cancer (HGSOC)
  • FAPI PET CT
  • (no location specified)
Jul 20, 2023

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovarian Cancer, High Grade Ovarian Serous Trial in New York (PET/MRI, Contrast enhanced CT)

Active, not recruiting
  • Ovarian Cancer
  • High Grade Ovarian Serous
  • PET/MRI
  • Contrast enhanced CT
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Mar 2, 2022

New Prognostic Index for Neoadjuvant Chemotherapy Outcome in

Enrolling by invitation
  • Ovarian Cancer
  • +2 more
  • CRS scoring
  • Routine blood laboratory testing before treatment
  • Guangzhou, Guangdong, China
    The Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Nov 2, 2023

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (Sovilnesib)

Not yet recruiting
  • High Grade Serous Adenocarcinoma of Ovary
  • +3 more
  • (no location specified)
Oct 13, 2023

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • (no location specified)
Oct 27, 2022

Multi-layer Data to Improve Diagnosis, Predict Therapy

Recruiting
  • High Grade Ovarian Serous Adenocarcinoma
  • WGS and RNA sequencing
  • +2 more
  • Turku, Finland
    Turku University Hospital
Apr 26, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Cetntre
Sep 25, 2023

High Grade Serous Ovarian Cancer Trial in Montpellier (Blood sample and tissue sample)

Not yet recruiting
  • High Grade Serous Ovarian Cancer
  • Blood sample and tissue sample
  • Montpellier, France
    NOUGARET Stephanie
Oct 10, 2023

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +17 more
  • Biopsy
  • +3 more
  • Augusta, Georgia
  • +4 more
Jan 25, 2023

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Ovarian Cancer Trial in Kelowna, Vancouver, Kingston (Durvalumab, BA3011, BA3021)

Recruiting
  • Ovarian Cancer
  • Kelowna, British Columbia, Canada
  • +4 more
Nov 14, 2022

CINSARC Genomic Signature as Predictor of Resectability of

Completed
  • Ovarian Adenocarcinoma
  • CINSARC signature
  • Toulouse, France
    Institut Claudius Regaud Institut Universitaire du cancer Toulou
Dec 22, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Platinum-resistant Ovarian Cancer Trial in China (IN10018 in combination with PLD)

Recruiting
  • Platinum-resistant Ovarian Cancer
  • IN10018 in combination with PLD
  • Anyang, China
  • +6 more
Sep 20, 2022

Investigate Adaptation and Evolution of Ovarian High-grade

Recruiting
  • Ovarian Cancer
  • +6 more
    • Bristol, United Kingdom
    • +10 more
    Sep 8, 2022